174 related articles for article (PubMed ID: 31180521)
1. PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.
Yu Z; Li Q; Zhang G; Lv C; Dong Q; Fu C; Kong C; Zeng Y
Int J Oncol; 2019 Jul; 55(1):81-92. PubMed ID: 31180521
[TBL] [Abstract][Full Text] [Related]
2. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.
Zhang G; Yu Z; Fu S; Lv C; Dong Q; Fu C; Kong C; Zeng Y
Cancer Gene Ther; 2019 Sep; 26(9-10):323-333. PubMed ID: 30459398
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.
Wu CW; Wu YG; Cheng C; Hong ZD; Shi ZM; Lin SQ; Li J; He XY; Zhu AY
Cell Physiol Biochem; 2018; 47(1):191-200. PubMed ID: 29763892
[TBL] [Abstract][Full Text] [Related]
6. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
Hao P; Kang B; Li Y; Hao W; Ma F
Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
[TBL] [Abstract][Full Text] [Related]
7. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
8. Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma.
Liu F; Li N; Liu Y; Zhang J; Zhang J; Wang Z
J Cell Biochem; 2019 Jun; 120(6):10391-10401. PubMed ID: 30609136
[TBL] [Abstract][Full Text] [Related]
9. miR-206 inhibits renal cell cancer growth by targeting GAK.
Wei C; Wang S; Ye ZQ; Chen ZQ
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):852-858. PubMed ID: 27924503
[TBL] [Abstract][Full Text] [Related]
10. SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation.
Liu Y; Chen JB; Zhang M; Zhang XL; Meng JL; Zhou J; Hao ZY; Zhang L; Zu XB; Liang CZ
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2756-2767. PubMed ID: 31002126
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ribosomal protein S15A inhibits human kidney cancer cell growth in vitro and in vivo.
Liang J; Liu Z; Zou Z; Wang X; Tang Y; Zhou C; Wu K; Zhang F; Lu Y
Mol Med Rep; 2019 Feb; 19(2):1117-1127. PubMed ID: 30569143
[TBL] [Abstract][Full Text] [Related]
12. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
Li CY; Yao AM; Chang XN; Guo YH; Xu R
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
[TBL] [Abstract][Full Text] [Related]
13. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).
Baumunk D; Reichelt U; Hildebrandt J; Krause H; Ebbing J; Cash H; Miller K; Schostak M; Weikert S
World J Urol; 2013 Oct; 31(5):1191-6. PubMed ID: 22544372
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Zheng J; Qin W; Jiao D; Ren J; Wei M; Shi S; Xi W; Wang H; Yang AG; Huan Y; Wen W
Int J Cancer; 2016 Oct; 139(7):1574-85. PubMed ID: 27193872
[TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway.
Li Z; Ma Z; Xu X
Oncol Rep; 2019 Feb; 41(2):1113-1121. PubMed ID: 30431104
[TBL] [Abstract][Full Text] [Related]
16. ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma.
Wu DS; Chen C; Wu ZJ; Liu B; Gao L; Yang Q; Chen W; Chen JM; Bao Y; Qu L; Wang LH
J Exp Clin Cancer Res; 2016 Jul; 35(1):108. PubMed ID: 27377902
[TBL] [Abstract][Full Text] [Related]
17. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.
Tang J; Wang F; Cheng G; Si S; Sun X; Han J; Yu H; Zhang W; Lv Q; Wei JF; Yang H
J Exp Clin Cancer Res; 2018 Feb; 37(1):40. PubMed ID: 29482572
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
[TBL] [Abstract][Full Text] [Related]
19. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
20. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
